predictors of availability of long-acting medication for opioid use disorder论文资料.pdf
Drug and Alcohol Dependence 204 (2019) 107586 Contents lists available at ScienceDirect Drug and Alcohol Dependence journal homepage: Predictors of availability of long-acting medication for opioid use disorder T ⁎ Chelsea L. Shovera, , Keith Humphreysa,b a Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Rd. (MC: 5717), Stanford, CA 94305, United States b Veterans Affairs Palo Alto Health Care System, 3801 Miranda Ave (152-MPD), Palo Alto, CA 94304, United States ARTICLE INFO ABSTRACT Keywords: Background: The . Food and Drug Administration has approved three long-acting medications for opioid use Opioid use disorder disorder (MOUD): extended-release naltrexone (XR-NTX) in 2010, a subdermal buprenorphine implant in 2016, Naltrexone and a depot buprenorphine injection in 2017. Long-acting MOUD options may improve adherence while re- B
predictors of availability of long-acting medication for opioid use disorder论文资料 来自淘豆网www.taodocs.com转载请标明出处.